Skip to main content
. 2018 Jul 23;2:PO.17.00211. doi: 10.1200/PO.17.00211

Fig 3.

Fig 3.

Genetic alterations related to potential targeted therapies. (A) Mutation rate and microsatellite instability (MSI) in patients with triple-negative breast cancer in Japan (n = 53); three (5.7%) of 53 hypermutated. (B) Mutation rate data from whole-exome sequencing (WES) for The Cancer Genome Atlas cohort (n = 123) were downsampled to the content of the 435-gene panel platform; six (4.9%) of 123 hypermutated. Inset: correlation between mutation rates determined by 435-gene panel and WES.